Nurix Therapeutics, Inc. (NRIX)
26.27
-0.45
(-1.68%)
USD |
NASDAQ |
Aug 24, 16:00
26.28
+0.01
(+0.04%)
After-Hours: 20:00
Nurix Therapeutics Revenue (Quarterly) : 9.043M for May 31, 2026
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 9.043M |
| February 28, 2026 | 6.252M |
| November 30, 2025 | 13.58M |
| August 31, 2025 | 7.894M |
| May 31, 2025 | 44.06M |
| February 28, 2025 | 18.45M |
| November 30, 2024 | 13.28M |
| August 31, 2024 | 12.59M |
| May 31, 2024 | 12.09M |
| February 29, 2024 | 16.58M |
| November 30, 2023 | 15.16M |
| August 31, 2023 | 18.47M |
| May 31, 2023 | 30.68M |
| February 28, 2023 | 12.68M |
| November 30, 2022 | 6.783M |
| Date | Value |
|---|---|
| August 31, 2022 | 10.79M |
| May 31, 2022 | 11.43M |
| February 28, 2022 | 9.621M |
| November 30, 2021 | 7.396M |
| August 31, 2021 | 10.25M |
| May 31, 2021 | 7.091M |
| February 28, 2021 | 5.011M |
| November 30, 2020 | 6.689M |
| August 31, 2020 | 4.085M |
| May 31, 2020 | 4.182M |
| February 29, 2020 | 2.864M |
| November 30, 2019 | 1.862M |
| August 31, 2019 | 10.58M |
| May 31, 2019 | 9.439M |
| February 28, 2019 | 9.234M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| Monte Rosa Therapeutics, Inc. | 8.968M |
| Gilead Sciences, Inc. | 7.821B |
| TG Therapeutics, Inc. | 240.34M |
| Cue Biopharma, Inc. | 7.877M |
| Keros Therapeutics, Inc. | 0.00 |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -89.54M |
| Total Expenses (Quarterly) | 98.58M |
| EPS Diluted (Quarterly) | -0.806 |
| Enterprise Value | 2.339B |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -990.1% |
| Earnings Yield | -13.12% |
| Normalized Earnings Yield | -13.12 |